Last reviewed · How we verify
Insulin Lispro Biphasic 25
Insulin Lispro Biphasic 25 is a premixed insulin formulation that rapidly lowers blood glucose by facilitating cellular glucose uptake and storage.
Insulin Lispro Biphasic 25 is a premixed insulin formulation that rapidly lowers blood glucose by facilitating cellular glucose uptake and storage. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin Lispro Biphasic 25 |
|---|---|
| Sponsor | Geropharm |
| Drug class | Premixed insulin (rapid-acting + intermediate-acting) |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
This biphasic insulin combines 25% rapid-acting insulin lispro with 75% intermediate-acting insulin isophane (NPH), providing both immediate and sustained glucose control. Insulin lispro is a rapid-acting analog that binds to insulin receptors on muscle and adipose tissue, promoting glucose uptake and glycogen synthesis, while the NPH component provides basal coverage over several hours.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Premixed vs Basal Bolus Insulin Therapy in Older Patients With Type 2 Diabetes (PHASE4)
- Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients (PHASE3)
- A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Lispro Mix 25 to Humalog® Mix 25 in Healthy Subjects (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |